HAMBURG, Germany, March 17, 2025--(BUSINESS WIRE)--Topas Therapeutics today announced the publication of data highlighting the ability of its proprietary antigen-coupled nanoparticles’ to ...

Publication supports Topas’ approach to generating immune tolerance through in vivo autoimmune disease model data in type 1 diabetes and multiple sclerosis Topas’ platform leverages the capability of ...